Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 7/2014

01-08-2014 | Original Article

68Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin

Authors: Omar Alonso, Mónica Rodríguez-Taroco, Eduardo Savio, Cecilia Bentancourt, Juan P. Gambini, Henry Engler

Published in: Annals of Nuclear Medicine | Issue 7/2014

Login to get access

Abstract

Objective

There is little evidence regarding the role of 68Ga-DOTATATE PET/CT for the identification of primary tumors in patients with metastatic neuroendocrine carcinoma of unknown primary. The aim of this study is to assess the value of this technique in the mentioned clinical scenario.

Methods

We retrospectively studied twenty-nine patients (mean age 59.5 ± 10.6 years; female 17) with pathologically proven neuroendocrine metastases. In all cases conventional imaging was negative for primary tumor identification. 68Ga-DOTATATE PET/CT was performed with a mean dose of 104.2 ± 18.8 MBq, using a 64-slice PET/CT with time-of-flight correction. A team of an experienced radiologist and a nuclear medicine physician evaluated the images. The maximum SUV (SUVm) was measured in all abnormal foci. Histopathology (when available) and/or clinical follow-up with correlative imaging was considered as reference standard.

Results

68Ga-DOTATATE PET/CT identified the primary tumor in 17/29 (59 %) patients in the following locations: pancreas (n = 7), ileum (n = 7), duodenum (n = 1), colon (n = 1) and stomach (n = 1). In this population a significant correlation was found between SUVm of primary tumor and metastases (r = 0.815, P < 0.0001). Furthermore, additional sites of unsuspected metastases were demonstrated in 9 patients of this group and in 6 patients in whom no primary tumor was localized, mainly in lymph nodes and mesentery. Pathology confirmation was obtained in 7 patients who underwent surgery, whereas in the remaining 10 patients, correlative imaging and follow-up confirmed primary tumor localization.

Conclusions

68Ga-DOTATATE PET/CT is a clinically useful imaging technique for the localization of primary tumors in patients with neuroendocrine metastatic carcinoma of unknown origin with the potential of having a significant impact in patient management and therapy planning.
Literature
1.
2.
3.
Stoyianni A, Pentheroudakis G, Pavlidis N. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors. Cancer Treat Rev. 2011;37:358–65.PubMedCrossRef
4.
Taylor MB, Bromham NR, Arnold SE. Carcinoma of unknown primary: key radiological issues from the recent National Institute for Health and Clinical Excellence guidelines. Br J Radiol. 2012;85:661–71.PubMedCentralPubMedCrossRef
5.
de Bresser J, de Vos B, van der Ent F, Hulsewé K. Breast MRI in clinically and mammographically occult breast cancer presenting with an axillary metastasis: a systematic review. Eur J Surg Oncol. 2010;36:114–9.PubMedCrossRef
6.
Seve P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007;109:292–9.PubMedCrossRef
7.
Moller AK, Loft A, Berthelsen AK, Damgaard Pedersen K, Graff J, Christensen CB, et al. 18F-FDG PET/CT as diagnostic tool in patients with extracervical carcinoma of unknown primary site: a literature review. Oncologist. 2011;16:445–51.PubMedCentralPubMedCrossRef
8.
Johansen J, Buus S, Loft A, Keiding S, Overgaard M, Hansen HS, et al. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck. 2008;30:471–8.PubMedCrossRef
9.
Adams S, Baum R, Rink T, Schumm-Drager PM, Usadel KH, Hor G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med. 1998;25:79–83.PubMedCrossRef
10.
Wong KK, Waterfield RT, Marzola MC, Scarsbrook AF, Chowdhury FU, Gross MD, et al. Contemporary nuclear medicine imaging of neuroendocrine tumors. Clin Radiol. 2012;67:1035–50.PubMedCrossRef
11.
Ramage JK, Ahmed A, Ardill J, Bax N, Breen DJ, Caplin ME, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine tumors (NETs). Gut. 2012;61:6–32.PubMedCentralPubMedCrossRef
12.
Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68 Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37:67–77.PubMed
13.
Naswa N, Sharma P, Kumar A, Soundararajan R, Kumar R, Malhotra A, et al. 68 Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin Nucl Med. 2012;37:245–51.PubMedCrossRef
14.
Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol. 2013;20:285–314.PubMedCrossRef
15.
Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Fave GD, Falconi M. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg. 2012;99:1480–6.PubMedCrossRef
16.
Baum RP, Kulkarni HR. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy—the Bad Berka experience. Theranostics. 2012;2:437–47.PubMedCentralPubMedCrossRef
17.
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WAP, Kooij PPM, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe]- and [123I-TYR]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716–31.PubMedCrossRef
18.
Savelli G, Lucignani G, Seregni E, Marchiano A, Serafini G, Aliberti G, et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun. 2004;25:445–9.PubMedCrossRef
19.
Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68 Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51:875–82.PubMedCrossRef
20.
Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68 Ga-DOTATOC versus 68 Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864–70.PubMedCrossRef
21.
Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2013. doi:10.​1177/​0284185113496679​.
22.
Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68 Ga-DOTATATE and 68 Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:1271–7.PubMed
23.
Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68 Ga-DOTANOC and 68 Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364–72.PubMedCrossRef
Metadata
Title
68Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin
Authors
Omar Alonso
Mónica Rodríguez-Taroco
Eduardo Savio
Cecilia Bentancourt
Juan P. Gambini
Henry Engler
Publication date
01-08-2014
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 7/2014
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-014-0856-3

Other articles of this Issue 7/2014

Annals of Nuclear Medicine 7/2014 Go to the issue

Others

Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 2.0

Original Article

Usefulness of 99mTc-pertechnetate whole body scan with neck and chest SPECT/CT for detection of post-surgical thyroid remnant and metastasis in differentiated thyroid cancer patients

Original Article

The usefulness of gated blood pool scintigraphy for right ventricular function evaluation in pulmonary embolism patients

Original Article

Inferior glucose metabolism and chemosensitivity of post-radiotherapy local recurrence in comparison with distant metastases as assessed by sequential 18F-FDG PET/CT imaging

Original Article

Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients

Original Article

Right ventricular 18F-FDG uptake is an important indicator for cardiac involvement in patients with suspected cardiac sarcoidosis